© BusinessWire
07.01.2025
SLP
LISTED
NASDAQ
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024.
First Quarter 2025 Financial...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
HNSA
LISTED
STO
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
News Preview
LUND, Sweden, Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at ir@hansabiopharma.com.
The Company has achieved several key mileston...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
HNSA
LISTED
STO
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
News Preview
LUND, Sweden, Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at ir@hansabiopharma.com.
The Company has achieved several key mileston...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
07.01.2025
ZEAL
LISTED
CPH
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
News Preview
Press Release – No. 2 / 2025...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
07.01.2025
RAY B
LISTED
STO
RaySearch receives first order for DrugLog
News Preview
STOCKHOLM, Jan. 7, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) today announces that the Polish company Medim has placed an order for the product DrugLog™. The order is a result of Medim winning a tender from The Children's Memorial Health Institute in Warsaw, Poland.
DrugLog is RaySearch's cost-effective solution for quickly and effic...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
TEM
LISTED
NASDAQ
Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan Healthcare on January 13-16, 2025, in San Francisco, CA.
Company Presentation | Tempus Founder and CEO, Eric Lefkofsky, will deliver a presentation and host a Q&A with...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
RXRX
LISTED
NASDAQ
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
News Preview
Salt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared a clinical trial application (CTA) for a Phase 1 clinical trial of REC-3565,...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ANAB
LISTED
NASDAQ
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 20...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
ICLR
LISTED
NASDAQ
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3.45pm PST.
Any changes to this event and links to the live webcast will be posted on the In...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
ORNBV
LISTED
HEL
Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide
News Preview
ORION CORPORATION INVESTOR NEWS 7 JANUARY 2025 at 9:00 EET...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
FAGR
LISTED
EURONEXT
Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 Jan 2025 – 7AM CET...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
TFX
LISTED
NYSE
Glancy Prongay & Murray LLP Announces Investigation of Teleflex Incorporated (TFX)
News Preview
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors’ and officers’ possible violations of state laws.
If you own Teleflex stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ActuNews
06.01.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC
News Preview
Leuven, BELGIË – 6 januari 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparan...
Themefolio
Profiler
Peergroup
© ActuNews
06.01.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
News Preview
Leuven, BELGIUM – January 6, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on January 6, 2025, from At...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
OSE
LISTED
EURONEXT
Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
POAI
LISTED
NASDAQ
POAI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Predictive Oncology Inc. Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Predictive Oncology Inc. (NASDAQ: POAI) to Renovaro Inc. is fair to Predictive shareholders.
Halper Sadeh encourages Predictive shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-00...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
ZEAL
LISTED
CPH
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
News Preview
Press Release – No. 1 / 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
LIVN
LISTED
NASDAQ
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer.
“Natalia...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
CYRX
LISTED
NASDAQ
Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA")
News Preview
All Three MVE Biological Solutions' Manufacturing Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed
NASHVILLE, Tenn., Jan. 6, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced that MVE Biological Solutions ("MVE"), a Cry...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
POAI
LISTED
NASDAQ
Predictive Oncology Announces Agreement to be Acquired by Renovaro
News Preview
- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
IMCR
LISTED
NASDAQ
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
GMAB
LISTED
CPH
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Media ReleaseCOPENHAGEN, Denmark; January 03, 2025Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco at 3:00 PM PST / 6:00 PM EST on January 14, 2025, 12:00 AM CET on January 15, 2025. The live and archived webcast of t...
Themefolio
Profiler
Peergroup
© ActuNews
03.01.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 6 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 150.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om he...
Themefolio
Profiler
Peergroup
© ActuNews
03.01.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential ma...
Themefolio
Profiler
Peergroup
© ActuNews
03.01.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC
News Preview
Leuven, BELGIË – 3 januari 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparan...
Themefolio
Profiler
Peergroup
© ActuNews
03.01.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
News Preview
Leuven, BELGIUM – January 3, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on December 30, 2024, from...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal’s Investor Relati...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
NSIS B
LISTED
CPH
Trading by management and close relations of management
News Preview
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.01.2025
IMCR
LISTED
NASDAQ
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
News Preview
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
IMMNOV
LISTED
STO
The exercise period for warrants of series TO 2 beings today: Immunovia AB
News Preview
LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025.
Summarized terms for the...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
IMMNOV
LISTED
STO
The exercise period for warrants of series TO 2 beings today: Immunovia AB
News Preview
LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025.
Summarized terms for the...
Themefolio
Profiler
Peergroup
© ActuNews
31.12.2024
OXUR
LISTED
EURONEXT
Oxurion kondigt uitstel aan van ondertekening van strategische transactie wegens lopende besprekingen
News Preview
Leuven, België – 31 december 2024 – 18u00 CET - Oxurion NV (Euronext Brussels: OXUR), een biofarmaceutisch bedrijf met hoofdzetel in Leuven, kondigt een kort uitstel aan van ongeveer vier weken voor de ondertekening van de voorgenomen strategische transactie. Dit uitstel is het gevolg van lopende besprekingen tussen de partijen, in...
Themefolio
Profiler
Peergroup
© ActuNews
31.12.2024
OXUR
LISTED
EURONEXT
Oxurion Announces Postponement of Signing for Strategic Transaction Due to Ongoing Discussions
News Preview
LEUVEN, BELGIUM –31 December 2024 – 6:00PM, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces a short postponement of approximately four weeks for the signing of its contemplated strategic transaction. The delay is due to ongoing discussions between the parties, prompted by the better t...
Themefolio
Profiler
Peergroup
© ActuNews
31.12.2024
OXUR
LISTED
EURONEXT
Oxurion annonce le report de la signature de la transaction stratégique en raison de discussions en cours
News Preview
Louvain, BELGIQUE – 31 décembre 2024 – 18h00, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce un léger report d'environ quatre semaines de la signature de la transaction stratégique envisagée. Ce report est dû à des discussions en co...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.12.2024
IBAB
LISTED
EURONEXT
IBA - Information réglementée
News Preview
Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (M.B. 12.VI.2007) (ci-après, la « Loi »)...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
TRAW
LISTED
NASDAQ
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
News Preview
Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term value inflecting readouts
NEWTOWN, Pa., Dec. 30, 2024 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a cl...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.12.2024
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 43rd Annual J.P. Morg...
Themefolio
Profiler
Peergroup
© PR Newswire
28.12.2024
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
News Preview
LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading i...
Themefolio
Profiler
Peergroup
© PR Newswire
28.12.2024
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
News Preview
LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading i...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.12.2024
ZEAL
LISTED
CPH
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
News Preview
Company announcement – No. 53 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.12.2024
ZEAL
LISTED
CPH
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
News Preview
Company announcement – No. 52 / 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
ICLR
LISTED
NASDAQ
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024.
On TIME Magazine’s 2024 list of World’s Best Companies ICON was ranked as the highest clinical research organisation out of 1,000 companies for the second year in a row, and in it...
Themefolio
Profiler
Peergroup
© PR Newswire
23.12.2024
TRAW
LISTED
NASDAQ
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
News Preview
Investigational agent in development for treatment or prevention of H5N1 Bird Flu
Phase 1 dosing completed in healthy volunteers
Potent inhibition of drug-resistant and bird flu viruses in vitro
In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs
Phas...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.12.2024
IMCR
LISTED
NASDAQ
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
News Preview
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.12.2024
FAGR
LISTED
EURONEXT
Fagron updates on FDA communication regarding the June 2024 inspection at Wichita
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
RXRX
LISTED
NASDAQ
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
News Preview
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement re...
Themefolio
Profiler
Peergroup
© PR Newswire
20.12.2024
IMMNOV
LISTED
STO
Immunovia discovery study published in top protein research journal
News Preview
LUND, Sweden, Dec. 20, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research. The study is the...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
ZEAL
LISTED
CPH
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
News Preview
Company announcement – No. 51 / 2024...
Themefolio
Profiler
Peergroup
© ActuNews
19.12.2024
OXUR
LISTED
EURONEXT
OXURION : Franse autoriteiten keuren de strategische transactie van Oxurion goed onder specifieke voorwaarden
News Preview
Leuven, België – 19 december 2024 – 18u00 CET - Oxurion NV (Euronext Brussels: OXUR), een biofarmaceutisch bedrijf met hoofdzetel in Leuven, kondigt aan dat het Franse Ministerie van Economie, Financiën en Industrie de voorgenomen strategische transactie van de vennootschap heeft goedgekeurd.
De voorgenomen transactie, een bel...
Themefolio
Profiler
Peergroup
© ActuNews
19.12.2024
OXUR
LISTED
EURONEXT
OXURION : Les autorités françaises approuvent la transaction stratégique d'Oxurion, sous certaines conditions spécifiques
News Preview
Louvain, BELGIQUE – 19 décembre 2024 – 18h00, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce que le Ministère français de l'Économie, des Finances et de l'Industrie a approuvé la transaction stratégique envisagée par la...
Themefolio
Profiler
Peergroup
© ActuNews
19.12.2024
OXUR
LISTED
EURONEXT
OXURION : French Authorities Approve Oxurion's Strategic Transaction Under Specific Conditions
News Preview
LEUVEN, BELGIUM – 19 December 2024 – 6:00PM, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces that the French Ministry of the Economy, Finance and Industry has approved the Company's contemplated strategic transaction.
The contemplated transaction, which is a significant step in Ox...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
ORNBV
LISTED
HEL
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS19 DECEMBER 2024 at 19.00 EET...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
IMMNOV
LISTED
STO
End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding
News Preview
LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities that lie ahead in 2025.
In 2024 we rapidly delivered multiple key milestones to put Immunovia on a path to success
As 2024 began, we had recently completed a significant transformation...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
SN
LISTED
LSE
Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty
News Preview
Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
LEGN
LISTED
NASDAQ
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday,...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
DFTX
LISTED
NASDAQ
MindMed to Be Added to the Nasdaq Biotechnology Index
News Preview
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024.
“2024 has been a transform...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
SKYE
LISTED
NASDAQ
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
News Preview
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare conference on Thursday, January 16, 2025,...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
BIOA B
LISTED
STO
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
News Preview
STOCKHOLM, Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic's...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone
News Preview
STOCKHOLM, SWEDEN – December 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 23.8 million through a convertible loan to be used for the continuation of the company’s clinical study of golexanolone in primary biliary cholangitis. The convertible loan with attac...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
BIOA B
LISTED
STO
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
News Preview
STOCKHOLM, Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic's...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
